FDA’s release of the long-awaited first set of guidances
on the new biosimilar development pathway in the U.S. offers a good opportunity to reflect on how the new 351(k) pathway compares to the traditional drug development model.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?